JOINN Laboratories (China) Co., Ltd.

My bottom-line classification: JOINN is a cyclical-reversal candidate with a commodity overlay, and the A-share now carries bubble-like elements. The company itself is real, experienced and competitively relevant. The stock action is also real, but it is running ahead of what the normalized service business has yet proven. The market is paying for peak or near-peak macaque pricing, for backlog recovery to become margin recovery, and for the fair-value line to keep flattering earnings long enough that the bridge back to core CRO profit looks smooth. That is a demanding combination. The H-share discount shows another market is willing to ascribe a much lower value to the same enterprise.

Company History and Financial Review

Company history and listing path

JOINN was founded in 1995 in Beijing. The founder-chair, Feng Yuxia, trained in pharmacology at the Academy of Military Medical Sciences and worked in toxicology and drug-evaluation settings before starting the business; that background helps explain why JOINN began as a specialist in safety evaluation rather than as a broad outsourced-lab conglomerate. Company material and anniversary publications describe JOINN as an early pioneer in China’s GLP non-clinical research market and, in its own telling, one of the first dedicated drug-evaluation companies in the country.

The Shanghai IPO in 2017 was straightforward main-board equity financing, not a reverse merger or carve-out. It priced at CNY 12.51, listed on 2017-08-25 and brought in gross proceeds of about RMB 256.5 million. The story offered to the market was a direct one: a specialist non-clinical CRO with regulatory-grade capabilities and a long domestic operating record.

The Hong Kong listing in 2021 added a second capital-markets chapter. JOINN offered 43.3248 million H shares at HKD 151 and raised about HKD 6.286 billion net, assuming the over-allotment option was not exercised. That listing was pitched as a scaling move rather than a rescue financing: use public capital to deepen capacity, broaden the platform and connect the domestic franchise to global customers and investors.

Three stages matter in the company’s vertical history. The first was the long build-out phase from founding through the 2017 A-share listing, when JOINN accumulated regulatory know-how, GLP credentials and the trust of domestic innovators. The second was the 2020-2022 boom phase, when China biotech funding, outsourcing demand and primate scarcity all moved in JOINN’s favor. The third is the 2023-2026 transition, when pricing on legacy contracts compressed, core margins were squeezed, and primate fair-value swings became much more visible in reported earnings. The company is now trying to widen from a strong non-clinical base into a fuller “target to market launch” offering while the industry shifts underneath it, rather than reinventing itself from scratch.

Financial vertical review

The numbers show a company that had a powerful up-cycle and then a hard comedown. Revenue rose from RMB 1.08 billion in 2020 to RMB 1.52 billion in 2021 and RMB 2.27 billion in 2022, then plateaued at RMB 2.38 billion in 2023 before falling to RMB 2.02 billion in 2024 and RMB 1.66 billion in 2025. Attributable profit followed a much more violent path: RMB 313.0 million in 2020, RMB 557.5 million in 2021, RMB 1.074 billion in 2022, RMB 397.0 million in 2023, RMB 74.1 million in 2024 and RMB 297.8 million in 2025. Gross margin compressed from 51.2% in 2020 and 48.5% in 2021 to 47.7% in 2022, 41.2% in 2023, 25.1% in 2024 and 17.0% in 2025. That is not a normal “great business at a bad moment” chart. It is a margin structure that has been badly hit by mix, pricing and utilization.

Cash flow has held up better than the earnings headline because the reported profit line is being distorted by non-cash valuation items and because working-capital collection has not broken. Operating cash flow was RMB 437.7 million in 2020, RMB 684.7 million in 2021, RMB 945.4 million in 2022, RMB 622.0 million in 2023, RMB 337.4 million in 2024 and RMB 430.0 million in 2025. Over those five years, operating cash flow exceeded attributable profit in four of five years and averaged well above 1x net income. That is comforting on liquidity, but it does not rescue valuation. It mainly tells you the accounting distortions cut both ways: monkey gains flatter earnings in some periods, monkey losses depress them in others.

The balance sheet is strong in the narrow sense. At year-end 2025, total assets were RMB 9.68 billion, total liabilities were RMB 1.36 billion and equity attributable to shareholders was RMB 8.32 billion. The annual reports repeatedly describe liquidity as strong, with cash and equivalents at RMB 911.9 million at end-2025 and low leverage. This is not a funding-risk story. The real issue is earnings quality and capital productivity, not solvency.

The biological-asset line is where the vertical review becomes a different sort of analysis. JOINN’s annual reports show the fair-value swing went from a gain of RMB 125.3 million in 2021 to a gain of RMB 333.1 million in 2022, then a loss of RMB 288.8 million in 2023, a loss of RMB 122.9 million in 2024 and a gain of RMB 514.3 million in 2025. At the same time, the carrying value mix of biological assets shifted. Total carrying value was RMB 1.465 billion at end-2023, RMB 1.069 billion at end-2024 and RMB 1.289 billion at end-2025. More important than the totals is the current/non-current split: RMB 558.9 million current and RMB 905.7 million non-current at end-2023, RMB 383.1 million current and RMB 685.8 million non-current at end-2024, then RMB 668.3 million current and RMB 620.3 million non-current at end-2025. That suggests the stock of animals available for near-term study use increased materially in 2025, which makes the mark-to-market exposure more immediate.

Price and valuation history

The stock’s capital-markets history lines up with those financial stages. The A-share came public at CNY 12.51 in 2017. The H-share was sold at HKD 151 in 2021, near a period when investors globally were willing to pay very high multiples for outsourced life-science platforms. The 2021-2022 phase rewarded JOINN for being both a CRO and an owner of hard-to-source primate capacity. The 2023-2024 phase punished it for exactly the same reason: when the demand cycle rolled over and macaque prices softened, operating deleverage and biological-asset markdowns moved together. The 2026 rally has brought the stock back toward multi-year highs, but under very different fundamentals from those reflected in the cleanest growth years. Google Finance showed an A-share 52-week range of CNY 26.25 to CNY 55.68, with market cap around CNY 31.0 billion at the time of the snapshot; the July 27 close cited by Sina was CNY 49.70. Reuters had the H-share at HKD 23.88 intraday on July 28, with the prior close at HKD 25.02 and a 52-week range of HKD 15.13 to HKD 29.98.

Valuation labels have changed with the cycle. In the up-cycle, JOINN was sold as scarce-capacity growth. In the down-cycle, it looked like an overbuilt domestic CRO exposed to biotech funding stress. In the current leg, it is being priced partly as a cyclical recovery and partly as a unique way to gain exposure to rising macaque prices. The problem is that those labels imply different holding periods and different earnings bases. A recovery multiple on normalized service profit is one thing. A momentum multiple on paper biological-asset gains is something else. The A-share market is currently leaning much harder into the second label than the first.

Business Model and Industry

How the business machine really works

JOINN’s core machine is still simple to describe even if the reported numbers are not. Clients pay for non-clinical studies, usually toxicology-heavy and often long-cycle. That requires a dense mix of GLP systems, trained scientists, animal resources, pathology capability, regulatory know-how and turnaround reliability. The company website markets exactly that: FDA- and ICH-aligned non-clinical safety evaluation plus discovery and clinical-adjacent services. The annual reports show the revenue structure remains overwhelmingly concentrated in non-clinical studies: 97.8% of revenue in 2021, 97.6% in 2022 and 97.1% in 2023.

That service model has meaningful fixed-cost content. JOINN must keep laboratories staffed, qualified and validated; maintain compliant animal housing; run pathology and specialist test platforms; and continue adding capacity ahead of demand. When utilization is high and pricing is firm, those fixed costs give the company operating leverage. When backlog converts at low legacy prices, they do the opposite. Recent filings describe exactly that. The 2025 annual report attributed the revenue decline primarily to reduced project unit prices because of the lagged effect of earlier fierce competition. On the May 2026 investor call, management again said low-price legacy orders were still being digested, because new order improvement reaches reported revenue only with a lag.

The macaque herd changes the business model in a way most CROs do not share. Biological assets are simultaneously operating inputs and mark-to-market assets. JOINN uses them in studies, breeds them for future use, and revalues them at fair value. The valuation methodology is disclosed explicitly. Jones Lang LaSalle Corporate Appraisal and Advisory Limited values the company’s biological assets independently, at fair-value hierarchy Level 3, using a market approach for younger animals where market prices exist and a depreciated replacement cost approach for older breeding animals, with inputs that include age, gender, health status, breeding useful life, market prices and replacement cost. KPMG highlighted biological-asset valuation as a key audit matter in the 2025 annual report, noting the use of recent transaction prices, replacement cost by age cohort and annual raising costs.

A real moat exists here, but it is not one thing. The first moat is regulatory credibility and process depth. Non-clinical safety studies are not a commodity washing-machine line. A sponsor picks a provider partly for data acceptance risk, partly for delivery risk, and partly for problem-solving in complex designs such as reproductive toxicity, carcinogenicity or dependence studies. JOINN’s own order comments in 2023 and 2025 show it winning harder, longer-cycle studies and growing in antibody, peptide, ADC and nucleic-acid areas. That looks like customer trust, not just price competition.

The second moat is capacity plus animal supply. This matters more in an up-cycle than in a soft market, but when macaques tighten, the owner of compliant internal supply has both cost protection and scheduling credibility. That is one reason the market keeps coming back to JOINN whenever monkey prices rise. The annual reports show both a large biological-asset book and a disclosed sensitivity large enough to move earnings materially with price. A competitor buying primates externally has to absorb cash cost inflation without receiving an accounting uplift. JOINN gets both.

The third moat is switching friction rather than classical switching costs. Drug developers do not love switching non-clinical CROs midway through a program because of study design continuity, historical data, QA familiarity and documentation burden. That is especially true in more complicated safety packages. This is not software stickiness, but it is enough to matter.

The weak point is that none of these moats protects the company from an industry price war when biotech funding is weak. The 2023-2025 financial history makes that plain. The moat is real, but it is a cyclical moat, not an all-weather one. It protects JOINN better than lightly equipped peers in a squeeze; it does not make it immune to a squeeze.

Management, governance and policy backdrop

Feng Yuxia remains the defining figure. She founded the company, is chair, and her background is directly relevant to the business. Day-to-day operating communication now often runs through general manager and board secretary Gao Dapeng, with CFO Yu Aishui handling finance. That is not a governance red flag by itself. The caution comes from elsewhere. In March 2024, the Beijing CSRC bureau issued a warning letter to controlling shareholders Feng Yuxia and Zhou Zhiwen over late disclosure after cumulative shareholding changes related to H-share listing dilution and active selling crossed mandatory thresholds. That is not an existential governance failure, but it is a reminder that this is still a founder-controlled company where minority investors should not assume perfect disclosure discipline.

The policy backdrop cuts both ways. The company’s 2025 annual report explicitly noted that the U.S. FDA had stated an intention to gradually reduce animal testing in some non-clinical settings and shift toward new approach methodologies such as AI models, organoids and organ-on-a-chip systems. JOINN says it is investing in those platforms too. For the next few years, that is more a strategic watchpoint than a near-term earnings killer. For the five-year view, it matters. A company whose accounting profits are being amplified by primate values cannot afford to ignore technologies meant to use fewer primates.

Competitors and Current Fundamentals

Horizontal portrait of the peer set

JOINN has both direct and indirect peers, and mixing them carelessly leads to bad valuation work. The closest direct international reference is Charles River Laboratories, which combines research models, discovery and safety assessment at global scale. Charles River reported first-quarter 2026 revenue of $995.8 million, up 1.2% year on year, and had a July 2026 market cap around $10.9 billion. The comparison matters because Charles River shows what a broad, globally diversified non-clinical platform looks like: more diversified end markets, much deeper customer breadth, and less sensitivity to one local animal-price cycle.

Frontage is a more relevant cross-listed Asia comp when the question is outsourced lab services without the same level of primate optionality. Frontage’s market cap was around HKD 2.35 billion in late July 2026 and its P/E was about 43.8x. Medicilon is a domestic preclinical/discovery CRO with market cap around CNY 10.9 billion in late July 2026, but EPS was negative, so conventional P/E tells you little. Pharmaron and WuXi AppTec are broader Chinese outsourcing leaders rather than direct non-clinical twins. That difference is exactly why they matter in valuation framing. They show where the market prices greater diversification, larger customer sets and higher perceived execution quality: WuXi AppTec’s A-share P/E was about 18.2x, while Pharmaron’s was about 40.8x around late July 2026. JOINN’s A-share, by contrast, was around 75x TTM on Sina’s snapshot.

That comparison is the heart of the horizontal conclusion. Customers choose JOINN when they need Chinese non-clinical depth, primate access, and proven delivery on harder safety packages. They go to Charles River or the broader global platforms when they want geographic breadth, broader modality support and less concentration in one regulatory and funding ecosystem. They turn to WuXi or Pharmaron for much wider outsourcing menus. JOINN is therefore a niche leader in a strategically important choke point of the drug-development chain, not a platform monopoly. That is a good place to be operationally. It is a dangerous place to be when the stock market starts paying platform-multiple prices for a niche leader’s cyclical asset revaluation.

What is actually happening now

The last four quarters tell a mixed story. The operating front is getting less bad. Orders improved through 2025, backlog stabilized and then rose, Q1 2026 revenue returned to growth, and operating cash flow almost doubled year on year in Q1. Management said Q2 order volume and pricing continued the Q1 pattern and utilization stayed high. That is the part of the bull case that holds up.

The profit front is still being misread if investors stop at the headline. Q1 2026 showed the split in the cleanest form: attributable net profit RMB 238.4 million, but laboratory services and other businesses negative RMB 28.5 million, with biological-asset fair-value change contributing positive RMB 245.9 million and non-recurring items contributing the balance. H1 2026 guidance then widened the same story. That means the market is currently trading a real operating recovery wrapped inside a much larger valuation event driven by macaque prices. The operating recovery is the seed. The biological-asset line is the flame.

The market is also trading heat itself. On July 16, JOINN warned that its stock had risen sharply over three consecutive trading days, that there was a risk of overheated sentiment and irrational speculation, and that biological-asset fair value was subject to significant uncertainty. That sort of exchange-mandated abnormal-volatility language is not proof of a bubble. It is clear evidence that management and the exchange both saw narrative-driven trading in the name.

Valuation Analysis

Cash-flow passthrough and the earnings-quality bridge

A headline P/E ratio is the wrong starting point here. Sina’s late-July quote implied about 75x TTM P/E for the A-share. Yet earnings are being pulled around by a non-cash fair-value line. The better discipline is to ask what shareholders are getting in owner earnings from the service business after maintenance needs.

The operating-cash-flow to attributable-net-income ratio over 2021-2025 was roughly 1.23x, 0.88x, 1.57x, 4.55x and 1.44x. The median is comfortably above 1x, but that does not mean reported net income is conservative. It means profits are noisy and non-cash line items are meaningful. The 2025 report showed operating cash flow of RMB 430.0 million, while depreciation and amortization implied by the notes was roughly RMB 161.8 million for the year. The company does not separately disclose maintenance versus growth capex, but its own capacity commentary around Suzhou Phase II, Beijing expansion and the future Guangzhou site strongly suggests much of recent investment has been growth-oriented. Using depreciation-and-amortization as a rough maintenance proxy yields 2025 owner earnings of roughly RMB 268 million. On a CNY 37.3 billion market cap, that is an owner-earnings yield of only about 0.7%, well below the headline earnings yield and far below what a cyclical service name with accounting volatility should command.

The bridge below is the practical way to separate the commodity cycle from the service business.

Source: JOINN annual reports, Q1 2026 report, and H1 2026 earnings preview; 2024 and 2025 “service-business read-through” uses disclosed operating profit and biological-asset line items where a direct full-year service-profit disclosure was not surfaced.

The most important line in that table is the 2025 ex-bio operating picture, not the H1 2026 profit forecast. The year that looked like a recovery on net profit was still a year in which operating profit turned negative once the biological-asset gain was stripped out. That is why I do not think the current A-share valuation is anchored to normalized services economics. It is anchored to a belief that monkey prices stay high long enough for service margins to heal before the accounting tailwind fades.

Historical and peer valuation

Historically, the current A-share sits much closer to the hot end of its recent range than to a distressed trough. Google Finance showed a 52-week high of CNY 55.68 and a low of CNY 26.25. At CNY 49.70, the market is handing investors a multiple more typical of businesses with durable, visible earnings growth, not a recession multiple or a washed-out cyclical multiple.

Against peers, the valuation also looks stretched once the accounting distortions are kept in view. WuXi AppTec traded around 18.2x P/E, Pharmaron around 40.8x, and Frontage around 43.8x. Medicilon had no meaningful P/E because it was loss-making. JOINN near 75x TTM is therefore substantially more aggressive than larger, more diversified names with cleaner business mixes. The usual defense is that JOINN owns a scarce primate asset base that peers do not. That is true. It does not follow that the right response is to capitalize the fair-value line at premium growth multiples.

Absolute valuation scenarios

The valuation below refers to the A-share line, 603127.SHG, in CNY per share. It is scenario analysis inside a research framework, not investment advice.

Source basis: current price and market data as above; owner-earnings framing uses JOINN’s OCF, D&A cues, backlog data, Q1 2026 service-profit disclosure, and H1 2026 forecast split.

The expectation gap is straightforward. The market is pricing some combination of three things: macaque prices stay high, service margins recover, and the accounting tailwind persists long enough that investors never have to sit through the handoff from paper gains to real operating gains. That is a lot to ask. The next prints matter less for revenue than for the ex-monkey service number. If the interim report shows that laboratory services have turned clearly positive even before fair-value gains, the bull case will strengthen. If the core line remains near break-even while monkey profits dominate, the argument for multiple compression gets stronger.

The independent margin-of-safety recheck comes out harshly. At CNY 49.70, the stock trades at a very large premium to the conservative scenario and still above the optimistic scenario. If earnings were flat for three years at a rough owner-earnings level near 2025, the annualized return would be below the China 10-year government-bond yield, which stood around 1.73% in late July 2026. On that test, there is no margin of safety at this buy price. The verdict is none.

Cross-Synthesis Summary

What JOINN has really proved, and what the market is probably misjudging

Vertically, JOINN has proved something important. It has proved that a Chinese specialist non-clinical CRO can survive long enough, scale far enough and earn enough customer trust to remain relevant through several very different industry environments. The company has been operating for three decades, stayed alive through funding cycles, won harder study types, built real animal infrastructure and retained enough customer confidence that backlog could recover to RMB 2.6 billion in 2025 and around RMB 3.1 billion by Q1 2026. That is capability, not luck.

The harder question is what kind of capability it is. JOINN’s historic success came from three layers together: specialized scientific and regulatory know-how, timing into China’s biotech outsourcing expansion, and ownership of scarce animal resources. In the 2021-2022 boom, that combination looked unbeatable because service demand and primate pricing reinforced one another. In the 2023-2025 downturn, the same combination looked much less comfortable because low-price contracts and falling monkey values reinforced one another in the opposite direction. That tells you the business has an edge, but not an all-weather edge. Its strength is real and cyclical at the same time.

Horizontally, JOINN’s real advantage versus peers lies in one narrow but crucial corridor of drug development, where it has unusually strong local execution and unusually valuable internal animal supply, not in being bigger than everyone. Customers pick it for confidence in complex non-clinical delivery and, in tight markets, because it can secure resources that others may struggle to buy. That is a better advantage than a mere marketing slogan. The weakness is that this advantage does not fully protect margins when customer budgets are squeezed, and it creates a second problem in the stock market: investors become tempted to price the macaque inventory as if it were a perpetual listed commodity franchise.

That is where I think the market is most likely misjudging the name. The market is not wrong that JOINN benefits from rising monkey prices. It is wrong when it erases the distinction between accounting uplift and operating earning power. Q1 2026 and the H1 2026 preview already show the handoff has not happened yet. The company is telling investors, in numbers, that service profit remains weak while animal revaluation is doing the work. When a stock trades at a large premium to its own H-share and at a steep premium to larger, broader peers while that is true, the burden of proof should sit with the bull case, not the bear case.

For the next year, the most critical variables are four. First, whether H2 2026 and early 2027 revenue converts the order recovery into gross-margin recovery. Second, whether macaque prices stay high enough that the fair-value line keeps supporting earnings. Third, whether legacy low-price contracts are mostly gone by the time new high-price orders flow through. Fourth, whether sentiment in the A-share can stay hot despite the possibility of a colder reading in the interim report’s core profit line. For three years, the question becomes whether JOINN can restore a service-profit base that deserves valuation without needing the monkey cycle to carry it. For five years, the strategic question is whether non-animal new approach methodologies remain a sideshow or start to erode the scarcity value of the primate-heavy model.

JOINN becomes a better investment under two broad conditions. One path is operational: two or three reporting periods in which ex-monkey service profit is clearly positive, gross margin is moving back above the low-20s toward the mid-20s, and backlog remains strong without fresh price concessions. The other path is price: even if the operating picture stays mixed, an A-share valuation much closer to the H-share or to the conservative scenario would create room for error that does not exist now. The research judgment should be re-examined if the interim report proves the service line has already inflected materially upward, or if macaque scarcity proves more durable than the market currently assumes and turns a one-year accounting windfall into a multi-year economic advantage.

Bull reasons and bear reasons

Bull reasons:

• JOINN remains one of the strongest local franchises in China non-clinical safety work, with orders in harder and longer-cycle studies rising in 2023 and 2025.
• The company’s internal primate base is economically useful, not merely cosmetic, and becomes a real delivery and cost advantage when external supply tightens.
• 2025 order backlog of roughly RMB 2.6 billion and Q1 2026 backlog of roughly RMB 3.1 billion show the demand side is improving before the income statement fully reflects it.
• Q1 2026 operating cash flow nearly doubled year on year, which reduces liquidity risk and suggests customers are still paying.

Bear reasons:

• H1 2026 earnings are dominated by biological-asset revaluation; the core service business is still around break-even at best by the company’s own split.
• The A-share trades at a very large premium to the H-share and at a richer multiple than broader, better-diversified CRO peers.
• The company’s disclosed fair-value sensitivity means even modest primate-price moves can materially alter earnings, which is poor ground on which to pay premium multiples.
• The 2025 annual report itself notes the FDA’s push toward new approach methodologies that could, over time, reduce animal-testing intensity.
• The controlling shareholders received a CSRC warning letter in 2024 over delayed disclosure after shareholding changes crossed required thresholds.

Pre-mortem

One plausible 50% down script over the next three years is simple. Macaque procurement prices cool from the current stressed spot levels back toward the company’s year-end 2025 valuation anchor, the fair-value line swings from a 2026 gain to a flat or negative contribution, interim reports reveal that service margins are improving only slowly because low-price contracts were replaced by merely normal-price contracts, and the A-share premium over the H-share collapses as narrative trading fades. In that script, the market stops valuing JOINN on peak-cycle reported earnings and starts valuing it on normalized owner earnings. A move from roughly 75x headline P/E toward a high-teens or mid-20s multiple on normalized profit could indeed cut the share price in half.

A second script is more strategic. Chinese biotech funding improves enough to keep order volume healthy, but non-animal testing methods gain faster regulatory and customer traction than expected in certain study categories, reducing the long-dated scarcity premium attached to primates. JOINN then discovers that it owns a valuable but less strategically central asset base, while the market had valued it as if primate scarcity was a durable moat. That sort of multiple reset rarely happens gradually.

Final research conclusion

JOINN is a real company with a real niche: credible non-clinical safety work, real delivery capability and a biologic-asset base that matters in a tight market. What it is not, at least on the evidence available by 2026-07-28, is a clean high-quality compounder whose present earnings power justifies the A-share price on a normalized basis. The stock is being pulled higher by two things that should be separated but currently are not: an improving order book in the CRO business, and a much larger fair-value uplift in macaques. The first is constructive. The second is cyclical and accounting-heavy. They are being capitalized together.

At CNY 49.70, I do not think investors are being paid for that distinction. The valuation already assumes that the monkey cycle stays favorable long enough for service margins to recover cleanly, and it assumes the A-share can keep carrying a very large premium over the H-share while doing so. That can happen for a while. It is not a sound margin-of-safety setup. What would change my mind is two or more quarters showing that the service line is again clearly profitable before biological-asset gains, with backlog still strong and gross margin moving back toward a normal operating range. Another tender at a higher monkey price would not do it.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: high
• Suitable investor type: cyclical

【Investment rating】

• Rating: Avoid
• One-line thesis: The A-share is pricing macaque revaluation like durable operating profit, even though the core CRO business is only just beginning to recover.
• Three price signals:
  • 【Ideal Buy Price】19–24 CNY Basis: at least a 20% margin of safety below the conservative scenario value, where macaque prices normalize and service recovery remains partial.
  • Acceptable hold price: 27–37 CNY
  • Clearly overvalued price: 44 CNY and above
• Current-price classification: clearly overvalued
• Whether to wait for a better price: yes. A more interesting entry would require either a retreat into the low- to mid-20s, or proof that ex-monkey service profit has turned sustainably positive. The opportunity cost of waiting is missing a speculative continuation of the macaque narrative.
• Target holding horizon: 1–3 years
• Expected annualized return: conservative about negative 21%; base about negative 14%; optimistic about negative 7%, using the scenario values above on a three-year view
• Max-loss risk: about 50% or more if macaque prices normalize before service margins recover and the A/H premium compresses
• Reassessment-trigger signals:
  • If laboratory services and other businesses turn positive for two consecutive reporting periods before biological-asset gains
  • If backlog remains above RMB 3.0 billion while gross margin improves toward or above 25%
  • If disclosed biological-asset sensitivity falls materially because price exposure is lower or herd mix changes
  • If the A/H premium narrows sharply without a collapse in operating indicators
  • If new approach methodologies start displacing meaningful portions of non-clinical animal demand

【Valuation Range】

• current: 49.70 (close as of 2026-07-27)
• bear (conservative · ideal buy zone): [19, 24]
• base (fair · acceptable hold zone): [27, 37]
• bull (optimistic · above the clearly-overvalued line): [44, 52]

Key data tables

Source: JOINN annual reports, annual-report chair statements, and Q1 2026 report. Q1 2026 biological-asset figure is net-profit contribution as disclosed, not the statutory P&L line item.

Why these matter: orders and backlog tell you whether the operating business is truly healing or just being outshouted by monkey prices; the service-profit line tells you whether the healing is reaching the P&L; gross margin shows whether legacy low-price projects are actually clearing; macaque prices determine whether the accounting tailwind persists; cash conversion protects against the illusion of purely paper profits; the A/H premium shows whether mainland sentiment is outrunning fundamentals; and the still-unannounced interim-report publication timing is itself important because the forecast is preliminary and the full split will matter more than the headline. As of 2026-07-28, the HKEX title-search page showed the Q1 board-meeting notices and the H1 profit-warning filing, but no surfaced interim-results board-meeting notice yet.

Research uncertainties

Four blind spots matter most. First, the H1 2026 result available by the report date is still a preliminary earnings preview, not the full interim report, so the exact statutory split between core services, biological-asset revaluation and other items can still move. Second, the surfaced annual-report lines show there were more than 20,000 primates at end-2025, but they do not provide a clean public age-cohort table in the excerpts reviewed here; the current/non-current carrying-value split is therefore a better guide than a simple “headcount” story. Third, macaque spot prices are fragmented and tender prices are not identical to private commercial pricing, so the public-procurement series is directionally useful but not a perfect market index. Fourth, maintenance versus growth capex is not broken out explicitly by the company, so owner-earnings estimates necessarily use rough proxies rather than management guidance.

Sources

The most important primary sources for this report were JOINN’s 2025 annual report, 2023 annual report, 2021 annual report, the 2026 first-quarter report, and the 2026 interim earnings preview. Supporting market and peer data came from Reuters, HKEX, company websites, Google Finance, and selected Chinese financial media that quoted procurement tenders and investor-communication transcripts.

Other tickers mentioned

• 6127.HK: JOINN’s H-share line, used to assess the A/H valuation gap
• CRL.US: closest global reference for a broader non-clinical CRO and research-model platform
• 1521.HK: Frontage, a smaller lab-services peer without JOINN’s primate-valuation exposure
• 688202.SHG: Medicilon, a domestic preclinical CRO used to frame China-sector valuation and profitability
• 300759.SHE: Pharmaron, a broader Chinese CRO used as a scale-and-diversification comparator
• 603259.SHG: WuXi AppTec, a broader outsourcing benchmark with a much lower earnings multiple
• 300347.SHE: Tigermed, a clinical-CRO reference from the wider Chinese outsourcing peer set

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.